Skip to content
Screener

Interest Income at other companies

Vera Therapeutics logo
Vera TherapeuticsVERA
$6.36M-8.0%
Regenxbio logo
RegenxbioRGNX
$1.22M-63.8%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$779K+13.1%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$2.43M-3.3%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$3.39M+6.4%
Moderna logo
ModernaMRNA
$67M-17.3%

Other financials

Income statement

See full
Revenue$284.0K+279%
Operating income-$126.3M-18.3%
Net income-$127.1M-26.2%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$165.0M+40.6%
Total debt$114.4M+395%
Total equity$662.1M+28.5%
Total assets$1.1B+88.4%

Cash flow

See full
Operating cash flow-$105.3M-39.7%
CapEx$1.3M+3,010%
Free cash flow-$106.6M-41.4%

Valuation

See full
Market cap$2.55B+81.7%
Enterprise value$2.5B+90.9%
P/S35.9×-4,565×

Profitability

See full
Gross margin36.3%
Operating margin-569.7%-284pp
Net margin-544.1%-271pp
FCF margin-471%-235pp

Returns & leverage

See full
Return on equity-65.7%-0.1pp
Debt / equity0.2×+0.1×
Current ratio16.9×+5.9×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:31 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001590750-26-000018
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total operating expenses126,552106,842242,862200,780
Loss from operations(126,268)(106,767)(242,437)(200,633)
Other income (expense), net:
Interest income8,4906,54616,36214,086
Interest expense(8,307)(514)(11,769)(1,100)
Change in fair value of derivative liability(1,190)6,340
Other income (expense), net156(516)
Total other income (expense), net(851)6,03210,41712,986

Item 1. Financial Statements (Unaudited)

FAQ

What is Viridian Therapeutics, Inc.'s interest income?
Viridian Therapeutics, Inc. (VRDN) reported interest income of $8.49M in Q2 2026.
How has Viridian Therapeutics, Inc.'s interest income changed year-over-year?
Viridian Therapeutics, Inc.'s interest income increased by 29.7% year-over-year, from $6.55M to $8.49M.
What is the long-term trend for Viridian Therapeutics, Inc.'s interest income?
Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s interest income has grown at a 204.7% compound annual growth rate (CAGR), from $318K to $27.4M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.

Ask your AI about Viridian Therapeutics, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude